Prostamax is a bioregulator peptide derived from prostate tissue — one of the most clinically targeted organs in the Khavinson series of tissue-specific short peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology. Prostamax activates gene expression in prostatic epithelial and stromal cells through the characteristic epigenetic mechanism of the bioregulator series: the short peptide penetrates prostate cell nuclei, binds to histone-DNA complexes, and reactivates transcription of prostate-specific functional genes silenced by aging, androgen fluctuation, and chronic inflammatory exposure.

The prostate is uniquely vulnerable to the intersection of aging and hormonal change. As testosterone levels decline and DHT (dihydrotestosterone) signaling patterns shift with age, the prostate undergoes progressive histological and functional changes: stromal proliferation, epithelial changes, inflammatory infiltration, and the gradual development of benign prostatic hyperplasia (BPH) in the majority of aging men. These changes reflect partly epigenetic dysregulation — age-related silencing of genes governing normal prostate cell differentiation, anti-proliferative signaling, and anti-inflammatory response in prostatic tissue.

Prostamax targets this epigenetic component of prostatic aging. The peptide activates transcription of genes encoding anti-proliferative factors that normally constrain prostatic stromal expansion, differentiation markers that maintain normal epithelial architecture, anti-inflammatory cytokines and their signaling components, and proteins involved in androgen receptor pathway regulation. By restoring these gene expression programs, Prostamax supports the maintenance of normal prostate cell identity and function against the epigenetic drift that enables hyperplastic and inflammatory changes.

Research from the Khavinson group has demonstrated Prostamax effects in aging animal prostate tissue and in human clinical studies in elderly men with age-related prostatic dysfunction. In experimental models, Prostamax treatment reduced prostatic inflammatory infiltration, improved histological markers of normal glandular architecture, and reduced proliferative markers in prostatic stromal tissue. Human clinical outcomes in published work include improvements in urinary flow parameters (urinary symptom scores, peak flow rates), reduced post-void residual volume, and improvements in subjective lower urinary tract symptoms — the clinical manifestation of BPH.

The preventive dimension is significant: epigenetic silencing of anti-proliferative prostatic genes begins decades before BPH becomes symptomatic. Prostamax used as a preventive cycling protocol in middle-aged men may maintain prostatic tissue quality and delay the epigenetic changes that enable BPH development — a fundamentally different approach from alpha-blockers (symptom relief) or 5-alpha reductase inhibitors (DHT reduction) that address downstream consequences rather than the upstream epigenetic root.

Protocol: 2mg/day for 10 consecutive days, subcutaneously or intranasally, repeated 2–4 times per year. Combination with Testagen (testicular/testosterone bioregulator) provides complementary male reproductive system coverage — prostate tissue restoration alongside gonadal hormone axis epigenetic support.